» Articles » PMID: 27695661

Staufen1s Role As a Splicing Factor and a Disease Modifier in Myotonic Dystrophy Type I

Overview
Journal Rare Dis
Date 2016 Oct 4
PMID 27695661
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

In a recent issue of , we reported that the double-stranded RNA-binding protein, Staufen1, functions as a disease modifier in the neuromuscular disorder Myotonic Dystrophy Type I (DM1). In this work, we demonstrated that Staufen1 regulates the alternative splicing of exon 11 of the human Insulin Receptor, a highly studied missplicing event in DM1, through Alu elements located in an intronic region. Furthermore, we found that Staufen1 overexpression regulates numerous alternative splicing events, potentially resulting in both positive and negative effects in DM1. Here, we discuss our major findings and speculate on the details of the mechanisms by which Staufen1 could regulate alternative splicing, in both normal and DM1 conditions. Finally, we highlight the importance of disease modifiers, such as Staufen1, in the DM1 pathology in order to understand the complex disease phenotype and for future development of new therapeutic strategies.

Citing Articles

Large-scale evaluation of the ability of RNA-binding proteins to activate exon inclusion.

Schmok J, Jain M, Street L, Tankka A, Schafer D, Her H Nat Biotechnol. 2024; 42(9):1429-1441.

PMID: 38168984 PMC: 11389820. DOI: 10.1038/s41587-023-02014-0.


Adaptation of RiPCA for the Live-Cell Detection of mRNA-Protein Interactions.

Soueid D, Garner A Biochemistry. 2023; 62(23):3323-3336.

PMID: 37963240 PMC: 11466511. DOI: 10.1021/acs.biochem.3c00334.


RNA-binding protein signaling in adult neurogenesis.

Chan J, Sanchez-Vidana D, Anoopkumar-Dukie S, Li Y, Benson Wui-Man L Front Cell Dev Biol. 2022; 10:982549.

PMID: 36187492 PMC: 9523427. DOI: 10.3389/fcell.2022.982549.


MDM4 alternative splicing and implication in MDM4 targeted cancer therapies.

Wu J, Lu G, Wang X Am J Cancer Res. 2022; 11(12):5864-5880.

PMID: 35018230 PMC: 8727814.

References
1.
Klinck R, Fourrier A, Thibault P, Toutant J, Durand M, Lapointe E . RBFOX1 cooperates with MBNL1 to control splicing in muscle, including events altered in myotonic dystrophy type 1. PLoS One. 2014; 9(9):e107324. PMC: 4161394. DOI: 10.1371/journal.pone.0107324. View

2.
Gleghorn M, Gong C, Kielkopf C, Maquat L . Staufen1 dimerizes through a conserved motif and a degenerate dsRNA-binding domain to promote mRNA decay. Nat Struct Mol Biol. 2013; 20(4):515-24. PMC: 4096160. DOI: 10.1038/nsmb.2528. View

3.
Laurent F, Sureau A, Klein A, Trouslard F, Gasnier E, Furling D . New function for the RNA helicase p68/DDX5 as a modifier of MBNL1 activity on expanded CUG repeats. Nucleic Acids Res. 2011; 40(7):3159-71. PMC: 3326330. DOI: 10.1093/nar/gkr1228. View

4.
Orengo J, Ward A, Cooper T . Alternative splicing dysregulation secondary to skeletal muscle regeneration. Ann Neurol. 2011; 69(4):681-90. PMC: 3082633. DOI: 10.1002/ana.22278. View

5.
Kanadia R, Shin J, Yuan Y, Beattie S, Wheeler T, Thornton C . Reversal of RNA missplicing and myotonia after muscleblind overexpression in a mouse poly(CUG) model for myotonic dystrophy. Proc Natl Acad Sci U S A. 2006; 103(31):11748-53. PMC: 1544241. DOI: 10.1073/pnas.0604970103. View